Merck & Co. has settled a patent dispute with Glenmark Pharmaceuticals involving the cholesterol drug Zetia, one of its best-selling products. The lawsuit had been scheduled to go to trial in two days when the settlement was reached. Under the terms of the settlement, Glenmark can start selling its generic version of Zetia on December 12, 2016. The patent would have expired on April 25, 2017. Zetia, or ezetimibe, was launched in the U.S. in 2002. In addition to being one of Merck’s biggest sellers, Zetia is one of the two components of a newer cholesterol drug, Vytorin. The other component of Vytorin is Zocor, which is already available as a generic.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.